The company is investing substantially in plant expansions and manufacturing improvements over the next few years so it can produce more drugs more efficiently.
With sequestration currently in place to rein in government spending across the board, much of the $1 billion that user fees bring in over 2013 will be frozen, with the FDA unable to tap the funding. But now, those funds are the target of the FDA Safety Over Sequestration Act--or FDA SOS Act--a bipartisan bill that would exempt user fees from the mandatory budget cuts.
A new rule in the United Arab Emirates will allow its 14 drug manufacturers to start up production on generic drugs sooner so they will be available as soon as the branded products go off patent.
U.S. preclinical CRO Absorption Systems has signed a deal with Indian consulting firm Synerzys Lifecare, looking to pitch its testing services to the nation's growing generics market.
Pfizer has launched a joint venture with China's Zhejiang Hisun Pharmaceuticals, a contract API manufacturer, planning to develop, manufacture and commercialize off-patent pharmaceutical products in China.
Less than four months after it recalled 155,000 bottles of tainted eye solution from its plant in Gujarat, India, Sun Pharmaceutical Industries says it is taking steps to streamline and standardize its manufacturing.
Once finalized, Pernix hopes the acquisition will improve its profit margins on generics, while laying the foundation for developing future over-the-counter and prescription products, according to the pharma company
The pharmaceutical giant announced this week that it is investing $20 million in Nantong-based Novast Laboratories, while calling upon Covance to expand insulin research in the country.
Fresh off dropping $130 million to license AstraZeneca's Zomig, drug delivery firm Impax Pharmaceuticals faces a citation from the FDA for its manufacturing practices.
Indian genericsmaker Ranbaxy Laboratories is on a bit of an expansion binge.